key: cord-0834558-4c6ismmq
authors: Yazdani, Setayesh; De Maio, Nicola; Ding, Yining; Shahani, Vijay; Goldman, Nick; Schapira, Matthieu
title: The SARS-CoV-2 replication-transcription complex is a priority target for broad-spectrum pan-coronavirus drugs
date: 2021-03-23
journal: bioRxiv
DOI: 10.1101/2021.03.23.436637
sha: 39d4526010e680cd8da9d86ccceafd39e0d062cb
doc_id: 834558
cord_uid: 4c6ismmq

In the absence of effective treatment, COVID-19 is likely to remain a global disease burden. Compounding this threat is the near certainty that novel coronaviruses with pandemic potential will emerge in years to come. Pan-coronavirus drugs – agents active against both SARS-CoV-2 and other coronaviruses – would address both threats. A strategy to develop such broad-spectrum inhibitors is to pharmacologically target binding sites on SARS-CoV-2 proteins that are highly conserved in other known coronaviruses, the assumption being that any selective pressure to keep a site conserved across past viruses will apply to future ones. Here, we systematically mapped druggable binding pockets on the experimental structure of fifteen SARS-CoV-2 proteins and analyzed their variation across twenty-seven α- and β-coronaviruses and across thousands of SARS-CoV-2 samples from COVID-19 patients. We find that the two most conserved druggable sites are a pocket overlapping the RNA binding site of the helicase nsp13, and the catalytic site of the RNA-dependent RNA polymerase nsp12, both components of the viral replication-transcription complex. We present the data on a public web portal (https://www.thesgc.org/SARSCoV2_pocketome/) where users can interactively navigate individual protein structures and view the genetic variability of drug binding pockets in 3D.

2 will emerge in years to come. Pan-coronavirus drugs -agents active against both SARS-CoV-2 and other coronaviruses -would address both threats. A strategy to develop such broad-spectrum inhibitors is to pharmacologically target binding sites on SARS-CoV-2 proteins that are highly conserved in other known coronaviruses, the assumption being that any selective pressure to keep a site conserved across past viruses will apply to future ones. Here, we systematically mapped druggable binding pockets on the experimental structure of fifteen SARS-CoV-2 proteins and analyzed their variation across twenty-seven αand β-coronaviruses and across thousands of SARS-CoV-2 samples from COVID-19 patients. We find that the two most conserved druggable sites are a pocket overlapping the RNA binding site of the helicase nsp13, and the catalytic site of the RNA-dependent RNA polymerase nsp12, both components of the viral replication-transcription complex. We present the data on a public web portal (https://www.thesgc.org/SARSCoV2_pocketome/) where users can interactively navigate individual protein structures and view the genetic variability of drug binding pockets in 3D.

The coronavirus SARS-CoV-2 that emerged in late 2019 has so far caused over two million deaths worldwide. While the recent approval of the first vaccines is expected to terminate the pandemic nature of the epidemic, it is believed that COVID-19 will not be eradicated, emphasizing the need for drugs 1 therapeutics and prepare for the next pandemic threat, SARS-CoV-2 drug discovery efforts should focus on the development of pan-coronavirus agents. A first strategy is to target host proteins that are essential for the replication of past coronaviruses and may therefore be essential 3 for the replication of coronaviruses emerging in the future 2 . An alternative approach, and the focus of this work, is to identify drug binding sites in the SARS-CoV-2 proteome that are conserved across coronaviruses. An approved anti-COVID-19 drug binding such site could be rapidly deployed against future outbreaks of novel coronaviruses.

Recent reports provided valuable insight into the druggability of SARS-CoV-2 proteins 3 , on their variation in COVID-19 samples and on their divergence from SARS-CoV-1 and from a specific bat coronavirus 4 . The excellent accompanying COVID-3D web portal allows users to map mutations on SARS-CoV-2 protein structures. A powerful online interface for inspecting variations between the SARS-CoV-2 genome and other viruses was also developed 5 , but to our knowledge, no integrated analysis focusing on the genetic variability of drug binding pockets across the SARS-CoV-2 proteome was reported to date.

We analyzed the structures of all SARS-CoV-2 protein domains represented in the PDB. The proteins analyzed included non-structural proteins (nsp) nsp1, nsp3, nsp5, nsp9, nsp12, nsp13, nsp14 (a SARS-CoV-1 structure was used that shared 100% sequence identity with SARS-CoV-2 at the active site), nsp15, nsp16; structural proteins E (transmembrane domain), Spike; additional factors ORF3a, ORF7a, ORF8, ORF9b. We used the PocketFinder function 6 in ICM (Molsoft, San Diego) to find potential druggable binding sites and assessed their druggability using SiteMap (Schrodinger, NY) 7 . The druggability evaluated with SiteMap was in general agreement with a previous work using a different method 3 and varied widely from poorly druggable, such as the catalytic site of the endoribonuclease nsp15 (Druggability score [Dscore] < 0.8), to highly druggable, such as a functionally uncharacterized ectopic site of the methyltransferase nsp14 (Dscore >1.0) (Figure 1a ).

Since pathogenic coronaviruses responsible for mild or severe respiratory illness all belong to the genera alphacoronavirus (α-CoV) and betacoronavirus (β-CoV), we focused on these families to define the genetic variability of binding pockets found on the SARS-CoV-2 proteome 8 indicating that this site is not favorable for the discovery of pan-coronavirus inhibitors ( Figure   1b ). Conversely, a druggable channel partially overlapping with the RNA-binding site of the SARS-CcoV-2 helicase (nsp13) is highly conserved (>90% of residues lining the pocket are conserved across 27 αand β-coronaviruses) (Figure 1b) . Interestingly, nsp13 binds to the RNAdependent RNA polymerase (nsp12) to functionally couple helicase and polymerase activities 10 and we find that the catalytic site of nsp12 is also among the most conserved binding pockets in 5 the SARS-CoV-2 proteome (>90% conservation across 27 αand β-coronaviruses) (Figure 1a) .

These results support the notion of a strong selective pressure against genetic variability that may affect the function of the replication-transcription complex.

To further investigate genetic variability, we assessed mutation of residues lining our collection of binding pockets across thousands of SARS-CoV-2 samples from COVID-19 patients and found some correlation with amino-acid conservation across αand β-coronavirus genera (supplementary Figure S2 ). For instance, the nsp13 druggable channel that is highly conserved across αand β-coronaviruses is also conserved across SARS-CoV-2 samples: not a single residue lining this site was mutated across 15,000 samples. Conversely, the linoleic acid binding site of the Spike protein, which is poorly conserved across coronaviruses, is one of the most mutated across SARS-CoV-2 samples (38% residues mutated across 15,000 samples). Supplementary Table S1 .

Our effort to systematically map the genetic variability of putative drug binding sites onto 3D

structures of the SARS-CoV-2 proteome reveals medicinal chemistry strategies for the development of broad-spectrum coronavirus inhibitors. In particular, we find that pharmacologically targeting the viral replication-transcription complex is a promising avenue for the discovery of pan-coronavirus drugs. In this regard, compounds such as EIDD-280, an oral antiviral targeting the catalytic site of nsp12 and currently in phase II-III clinical trials against COVID-19 11 , represent promising drug candidates for current and future coronavirus pandemic threats. Similarly, targeting the RNA binding site of nsp13 is a priority -though underexploredavenue that may benefit from recent advances on the chemical inhibition of RNA-binding proteins 12 .

ASSOCIATED CONTENT Supporting Information. The following figures and tables are provided as supporting online information. Percent sequence identity and druggability of drug binding sites in the SARS-CoV-2 proteome represented in the PDB ( Figure S1 ); mutation level of residues lining drug binding

The Coronavirus Is Here to Stay -Here's What That Means

Genome-Scale Identification of SARS-CoV-2 and Pan-Coronavirus Host Factor Networks

Functional and Druggability Analysis of the SARS-CoV-2 Proteome

Exploring the Structural Distribution of Genetic Variation in SARS-CoV-2 with the COVID-3D Online Resource

The UCSC SARS-CoV-2 Genome Browser

Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes

Identifying and Characterizing Binding Sites and Assessing Druggability

Broad-Spectrum Coronavirus Antiviral Drug Discovery

Free Fatty Acid Binding Pocket in the Locked Structure of SARS-CoV-2 Spike Protein

Replication-Transcription Complex

Infection Is Effectively Treated and Prevented by EIDD-2801

Inhibition of RNA-Binding Proteins with Small Molecules